The role of serum immunoglobulin free light chain in response and progression in Waldenstrom macroglobulinemia

Clinical Cancer Research

Volumn 17, Issue 9, 2011, Pages 3013-3018

  Leleu, Xavier ^a,c   Xie, Wanling ^b   Bagshaw, Meghan ^a   Banwait, Ranjit ^a   Leduc, Renee ^a   Roper, Nitin ^a   Weller, Edie ^b   Ghobrial, Irene M ^a  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c LILLE UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN FREE LIGHT CHAIN; IMMUNOGLOBULIN LIGHT CHAIN; IMMUNOGLOBULIN M; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD ANALYSIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RELAPSE; CLINICAL ARTICLE; COHORT ANALYSIS; CORRELATIONAL STUDY; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MALE; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; WALDENSTROEM MACROGLOBULINEMIA;

ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOGLOBULIN LIGHT CHAINS; MALE; PYRAZINES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; WALDENSTROM MACROGLOBULINEMIA;

EID: 79955493103     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-2954     Document Type: Article

References (15)

1. Treon SP. How I treat Waldenstrom's macroglobulinemia. Blood 2009;270:2375-85.
2. Leleu X, Roccaro AM, Moreau AS, Dupire S, Robu D, Gay J, et al. Waldenstrom macroglobulinemia. Cancer Lett 2008;270:95-107.
3. Ghobrial IM, Witzig TEWaldenstrom macroglobulinemia. Curr Treat Options Oncol 2004;5:239-47.
4. Kimby E, Treon SP, Anagnostopoulos A, Dimopoulos M, Garcia-Sanz R, Gertz MA, et al. Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 2006;6:380-3.
5. Weber D, Treon SP, Emmanouilides C, Branagan AR, Byrd JC, Blade J, et al. Uniform response criteria in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:127-31. (Pubitemid 36506294)
6. Dispenzieri A, Kyle RA, Katzmann JA, Therneau TM, Larson D, Benson J, et al. Immunoglobulin free light chain ratio is an independent risk factor for progression of smoldering (asymptomatic) multiple myeloma. Blood 2008;111:785-9.
7. Mayo MM, Johns GS. Serum free light chains in the diagnosis and monitoring of patients with plasma cell dyscrasias. Contrib Nephrol 2007;153:44-65. (Pubitemid 44836014)
8. Abadie JM, Bankson DD. Assessment of serum free light chain assays for plasma cell disorder screening in a Veterans Affairs population. Ann Clin Lab Sci 2006;36:157-62.
9. Rajkumar SV. MGUS and smoldering multiple myeloma: update on pathogenesis, natural history, and management. Hematol Am Soc Hematol Educ Program 2005;340-5.
10. Mead GP, Carr-Smith HD, Drayson MT, Morgan GJ, Child JA, Bradwell AR. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004;126:348-54. (Pubitemid 39005714)
11. Nowrousian MR, Brandhorst D, Sammet C, Kellert M, Daniels R, Schuett P, et al. Serum free light chain analysis and urine immunofixation electrophoresis in patients with multiple myeloma. Clin Cancer Res 2005;11:8706-14. (Pubitemid 43005920)
12. Harding SJ, Mead GP, Bradwell AR, Berard AM. Serum free light chain immunoassay as an adjunct to serum protein electrophoresis and immunofixation electrophoresis in the detection of multiple myeloma and other B-cell malignancies. Clin Chem Lab Med 2009;47:302-4.
13. Katzmann JA, Abraham RS, Dispenzieri A, Lust JA, Kyle RA. Diagnostic performance of quantitative kappa and lambda free light chain assays in clinical practice. Clin Chem 2005;51:878-81. (Pubitemid 40577925)
14. Kyle RA, Rajkumar SV. Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma. Leukemia 2009;23:3-9.
15. van Rhee F, Bolejack V, Hollmig K, Pineda-Roman M, Anaissie E, Epstein J, et al. High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis. Blood 2007;110:827-32. (Pubitemid 47267417)